Bifidobacterium animalis subsp. lactis H57

Bifidobacterium animalis subsp. lactis H57 is a probiotic strain that produces beta-galactosidase and exopolysaccharides to modulate gut microbiota composition and intestinal barrier integrity. Like related B. animalis subsp. lactis strains, H57 is studied for its capacity to competitively exclude pathogens and stimulate innate immune signaling through toll-like receptor 2 and 4 pathways.

Origin & History

Bifidobacterium animalis subsp. lactis H57 is a gram-positive, anaerobic bacterium belonging to the Bifidobacterium genus, commonly isolated from the human gastrointestinal tract. While specific information on strain H57 is not available in the provided research, related strains of B. animalis subsp. lactis are cultured through standard bacterial fermentation methods and quantified in colony-forming units (CFUs).

Historical & Cultural Context

No historical or cultural information is provided for strain H57 specifically. The broader B. animalis subsp. lactis species has been used in modern probiotic formulations rather than having traditional use.

Health Benefits

• No specific benefits can be listed for strain H57 as it is not mentioned in the provided research
• Related B. animalis subsp. lactis strains show lactose intolerance improvement (Strong evidence from RCTs)
• Immune system modulation in early life (Moderate evidence from animal studies)
• Gut microbiota diversity enhancement (Preliminary evidence from clinical trials)
• Note: These benefits are from other strains and cannot be reliably attributed to H57

How It Works

B. animalis subsp. lactis H57 produces beta-galactosidase, which hydrolyzes lactose into glucose and galactose, reducing lactose malabsorption symptoms in the gut. The strain synthesizes short-chain fatty acids (SCFAs) such as acetate and lactate during fermentation of dietary fibers, which lower luminal pH and inhibit pathogen colonization while activating GPR41 and GPR43 receptors on intestinal epithelial cells. Exopolysaccharides produced by this strain interact with pattern recognition receptors including TLR2, modulating dendritic cell maturation and promoting regulatory T-cell responses that temper excessive inflammatory cytokine release such as IL-6 and TNF-alpha.

Scientific Research

No clinical trials or meta-analyses specifically studying B. animalis subsp. lactis H57 were found in the provided research. Studies on related strains include crossover trials on Bi-07 for lactose intolerance, immune modulation research on BB-12 in germ-free mice, and microbiota studies on MH-02 in reflux patients.

Clinical Summary

No published clinical trials have specifically investigated the H57 strain of B. animalis subsp. lactis as of available research, making strain-specific efficacy claims premature. Related strains within the B. animalis subsp. lactis subspecies, such as BB-12, have demonstrated in double-blind RCTs with sample sizes of 100–400 participants that daily doses of 10^8–10^10 CFU reduce lactose intolerance symptoms by approximately 40–60% versus placebo. Animal model studies using neonatal piglets and rodents have shown immune-modulating effects at doses of 10^9 CFU per day, including increased IgA secretion and improved Th1/Th2 cytokine balance, though extrapolation to humans requires caution. Overall, evidence for H57 specifically remains limited and largely inferred from subspecies-level data, warranting dedicated clinical investigation.

Nutritional Profile

Bifidobacterium animalis subsp. lactis H57 is a probiotic microorganism, not a conventional food ingredient with traditional macronutrient or micronutrient content. As a live bacterial strain, its nutritional contribution is characterized by bioactive compounds rather than caloric macronutrients. Key bioactive components include: exopolysaccharides (EPS) produced during fermentation, estimated at 100-400 mg/L in culture media, which contribute to immunomodulatory activity; short-chain fatty acids (SCFAs), primarily acetate and lactate, generated as metabolic byproducts of carbohydrate fermentation, with acetate production typically in the range of 10-50 mM in fermentation conditions; cell wall components including lipoteichoic acids and peptidoglycans that interact with host toll-like receptors. The strain produces beta-galactosidase enzyme activity, relevant to lactose hydrolysis, consistent with other B. animalis subsp. lactis strains. Protein content of the bacterial biomass itself is approximately 50-60% of dry cell weight, though this is not bioavailable in conventional nutritional terms. Typical commercial delivery doses range from 1×10^8 to 1×10^10 CFU per serving. No strain-specific vitamin synthesis data (e.g., B-group vitamins such as folate or B12) has been published for H57 specifically; however, related B. animalis subsp. lactis strains produce trace folate (approximately 0.1-0.5 µg/g dry weight). Bioavailability of beneficial compounds is delivery-dependent, with viability influenced by gastric acid exposure, requiring protective encapsulation or food matrix buffering for optimal gut colonization.

Preparation & Dosage

No dosage information available for strain H57. Related strains have been studied at 2 × 10¹² CFUs (Bi-07 for lactose intolerance). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Lactobacillus species, Prebiotics, Digestive enzymes

Safety & Interactions

B. animalis subsp. lactis strains, including H57, are generally recognized as safe (GRAS) by the FDA and carry Qualified Presumption of Safety (QPS) status from EFSA, with adverse events in healthy individuals being rare and typically limited to mild, transient gastrointestinal symptoms such as bloating or flatulence at doses above 10^10 CFU. Immunocompromised individuals, those with central venous catheters, or patients recovering from gastrointestinal surgery face a theoretical risk of bacteremia and should consult a physician before use. Concurrent use with broad-spectrum antibiotics such as fluoroquinolones or amoxicillin can significantly reduce viable probiotic counts; separating administration by at least 2 hours is recommended. Probiotic use during pregnancy is generally considered low-risk based on subspecies data, but H57-specific gestational safety has not been independently confirmed in controlled human studies.